AD Ports Group and Hayat Biotech have signed a Memorandum of Understanding (MoU) to support Hayat Biotech’s global logistics and distribution efforts through AD Ports Group’s advanced pharma logistics network.
The partnership will help facilitate Hayat Biotech’s efforts to set up manufacturing centres around the globe and provide logistics solutions to serve its international markets.
The initial element of the agreement encapsulates shipping of strategic construction supplies, including containers, machinery, raw materials, and equipment, to support the construction of Hayat Biotech’s global biopharmaceutical manufacturing facilities.
Once fully completed, the facilities will produce a number of vital biopharmaceutical products, including the Hayat-Vax vaccine, the first indigenously produced COVID-19 vaccine in the UAE and the Arab world.
The distribution will be handled by the HOPE Consortium, an Abu Dhabi-led partnership which operates one of the largest and most complete end-to-end pharma supply chains on the market.
Captain Mohamed Juma Al Shamisi, Managing Director and Group CEO of AD Ports Group, and Chairman of the HOPE Consortium’s Executive Committee, said: “As a nation, the UAE continues to take significant steps towards enabling global access to pharmaceutical products and supplies. Thanks to our partnership with Hayat Biotech, we are cementing the pivotal role that AD Ports Group and the HOPE Consortium are playing in supporting our healthcare industry’s efforts to serve communities and markets all around the world.”
He added: “AD Ports Group continues to deliver on our leadership’s vision of establishing Abu Dhabi as a global life sciences hub, and our partnership with Hayat Biotech is another important milestone along our journey towards achieving that goal.”
As a UAE-based company, Hayat Biotech, a Joint Venture between Abu Dhabi’s G42 and Sinopharm CNBG, focuses on the development of life sciences through advanced clinical trials, medical R&D, distribution of new pharmaceutical products, and vaccines.
The company began locally-producing the Hayat-Vax vaccine in March 2021, which has been distributed worldwide, in part, by the HOPE Consortium partnership.
Last year, Hayat Biotech announced the development of a purpose-built research and development hub for life sciences, biotechnology and vaccine production.
Set up in KIZAD, the facility will be capable of producing over 200 million vaccine doses annually.
The signing ceremony also saw the announcement of AD Ports Group’s office in Uzbekistan, the Group’s first in the Central Asia region.